AC Immune announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim CFO Christopher Roberts to CFO. Dr. Derouazi succeeds the former CSO, Dr. Marie Kosco-Vilbois, who is retiring and will remain with AC Immune as an expert consultant in immunology to ensure continuity and a smooth transition. Derouazi joins from Speransa Therapeutics where she had been CEO since inception in 2021, leading development of a novel platform of prophylactic vaccines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACIU:
- AC Immune to Present at the Jefferies 2023 London Healthcare Conference
- AC Immune reports Q3 EPS (18c), consensus 3c
- AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
- AC Immune announces data on ACI-12589 published in Nature Communications
- AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
